ALLO-329

ALLO-329 is an investigational allogeneic chimeric antigen receptor T-cell (CAR-T) therapy developed for the treatment of autoimmune diseases. It is a dual-targeting CAR-T product that utilizes CRISPR-based site-specific integration to express two chimeric antigen receptors targeting both CD19+ B cells and CD70+ activated T cells. This approach aims to address immune dysregulation by eliminating pathogenic B cells and activated T cells involved in the pathogenesis of autoimmune diseases. The therapy incorporates Allogene’s proprietary Dagger technology, which is designed to reduce or eliminate the need for lymphodepletion prior to cell infusion, potentially simplifying treatment protocols and expanding patient access. ALLO-329 has received FDA fast track designation for several rheumatologic indications and is being evaluated in a phase 1 basket study (RESOLUTION trial) across multiple autoimmune conditions including systemic lupus erythematosus (SLE), idiopathic inflammatory myopathies (IIM), scleroderma/systemic sclerosis (SSc), and lupus nephritis[1][3][4][5][6].

Other names

dual CD19-CD70 CAR-TCD19/CD70 dual AlloCAR T